DAVENPORT & Co LLC Lowers Stock Holdings in HCA Healthcare, Inc. $HCA

DAVENPORT & Co LLC reduced its position in HCA Healthcare, Inc. (NYSE:HCA) by 0.5% in the 2nd quarter, Holdings Channel reports. The fund owned 11,931 shares of the company’s stock after selling 54 shares during the period. DAVENPORT & Co LLC’s holdings in HCA Healthcare were worth $4,571,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. ORG Partners LLC grew its stake in HCA Healthcare by 27.9% in the 2nd quarter. ORG Partners LLC now owns 142 shares of the company’s stock worth $55,000 after acquiring an additional 31 shares during the period. Avantax Advisory Services Inc. grew its stake in shares of HCA Healthcare by 0.4% during the 1st quarter. Avantax Advisory Services Inc. now owns 8,077 shares of the company’s stock valued at $2,791,000 after buying an additional 32 shares during the period. Glenview Trust co grew its stake in shares of HCA Healthcare by 2.3% during the 1st quarter. Glenview Trust co now owns 1,451 shares of the company’s stock valued at $501,000 after buying an additional 32 shares during the period. Horizon Investments LLC grew its stake in shares of HCA Healthcare by 1.1% during the 1st quarter. Horizon Investments LLC now owns 3,175 shares of the company’s stock valued at $1,097,000 after buying an additional 33 shares during the period. Finally, Sivia Capital Partners LLC grew its stake in shares of HCA Healthcare by 5.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 630 shares of the company’s stock valued at $241,000 after buying an additional 33 shares during the period. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

Shares of HCA stock opened at $437.46 on Wednesday. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $439.01. The firm has a market capitalization of $102.36 billion, a P/E ratio of 18.39, a P/E/G ratio of 1.36 and a beta of 1.40. The company’s fifty day moving average price is $401.26 and its two-hundred day moving average price is $374.10.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, topping the consensus estimate of $6.20 by $0.64. The company had revenue of $18.61 billion during the quarter, compared to the consensus estimate of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, sell-side analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were given a $0.72 dividend. The ex-dividend date of this dividend was Tuesday, September 16th. This represents a $2.88 annualized dividend and a dividend yield of 0.7%. HCA Healthcare’s payout ratio is presently 12.11%.

Insider Buying and Selling at HCA Healthcare

In related news, EVP Michael S. Cuffe sold 3,836 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the sale, the executive vice president owned 31,503 shares of the company’s stock, valued at $13,194,716.52. This represents a 10.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on HCA shares. Bank of America boosted their price objective on shares of HCA Healthcare from $375.00 to $410.00 and gave the company a “neutral” rating in a research note on Wednesday, September 10th. Robert W. Baird lifted their target price on shares of HCA Healthcare from $380.00 to $423.00 and gave the company a “neutral” rating in a report on Thursday, August 14th. Barclays lifted their target price on shares of HCA Healthcare from $390.00 to $445.00 and gave the company an “overweight” rating in a report on Thursday, September 18th. Morgan Stanley reduced their target price on shares of HCA Healthcare from $410.00 to $400.00 and set an “equal weight” rating on the stock in a report on Monday, July 28th. Finally, JPMorgan Chase & Co. lifted their target price on shares of HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a report on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $410.83.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.